Effects of Losartan on Insulin Resistance in Patients With Heart Failure

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00663377

Recruitment Status : Completed

First Posted : April 22, 2008

Last Update Posted : April 22, 2008

Sponsor:

Information provided by:

Tottori University Hospital

Results Submitted - Not Posted on ClinicalTrials.gov

Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.

Recruitment Status :	Completed
Primary Completion Date :	No date given
Actual Study Completion Date :	March 2007

Submission Cycle	Results Submitted to ClinicalTrials.gov	Results Returned after Quality Control Review
1	July 20, 2011	August 15, 2011
2	August 18, 2011
3	November 16, 2011	December 20, 2011
4	June 3, 2012	July 6, 2012
5	July 12, 2012	August 20, 2012
6	September 25, 2012	October 26, 2012
7	November 14, 2012	December 11, 2012

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Ogino K, Kato M, Furuse Y, Kinugasa Y, Kaetsu Y, Mizuta E, Sugihara S, Ishida K, Yanagihara K, Hisatome I, Shigemasa C. Addition of losartan to angiotensin-converting enzyme inhibitors improves insulin resistance in patients with chronic heart failure treated without β-blockers. Circ J. 2010 Nov;74(11):2346-52. Epub 2010 Sep 4.

To Top